Hepatocellular carcinoma (HCC) diagnosis and management have undergone significant
improvements in recent years. With the introduction of immunotherapy-based combination …

This review examines the latest epidemiological and molecular pathogenic findings of
metabolic-associated hepatocellular carcinoma (HCC). Its increasing prevalence is a …

Background & aims Combination immunotherapy refers to the use of immune checkpoint
inhibitors (ICI) and molecular-targeted agents (MTA), which have recently been approved for …

With limited therapeutic options for hepatocellular carcinoma (HCC), it is of great
significance to investigate the underlying mechanisms and identifying tumor drivers. MCM6 …

The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

Introduction Hepatocellular carcinoma (HCC) is a primary liver cancer that commonly arises
in the background of chronic liver inflammation and/or cirrhosis. Chronic liver inflammation …

Abstract Purpose of Review The number of deaths due to hepatocellular carcinoma (HCC)
continues to rise. Chemoprevention may be a useful strategy to prevent HCC. Recent …

In recent years, novel drugs for hepatocellular carcinoma (HCC) have been consistently
approved, leading to a significant expansion of treatment options. However, the targets …

Correspondence to: Ju Dong Yang, MD. Karsh Division of Gastroenterology and
Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Comprehensive …

Rapid development of molecular-targeted and immunebased agents has substantially
expanded clinically available therapeutic options in HCC.[1] However, the limited response …